Bajaj Healthcare Ivejaj gets DCGI nod for COVID treatment
The drug will be available as a prescription-based medication, with recommended doses.
Thane: Bajaj Healthcare Limited (BHL) has recently announced the launch of "Ivejaj" (Ivermectin) an AntiParasitic Drug now widely used in control & treatment for Covid-19 patients.
BHL has received approval from India's drug regulator, to manufacture and market "Ivejaj" the oral Ivermectin approved medication in India for the treatment of COVID-19.
IVEJAJ Tablets comprising Ivermectin. Ivermectin is an Anti-Parasitic Drugs, which is used to control parasitic roundworm infections and curing parasitic infections, helps to improve health of Covid-19 Patients. It works by paralyzing and killing parasites.
Commenting on the launch of "Ivejaj" (Ivermectin), Mr. Anil Jain, Joint Managing Director, Bajaj Healthcare said "We are pleased to add Ivermectin to our growing product portfolios. The second waves is more aggressive and bigger in number than the first. We hope the availability of an effective treatment such as Ivejaj will considerably ease the pressure and offer patients much needed and timely therapy option."
BHL has successfully developed the active pharmaceutical ingredient (API) and the formulation for Ivermectin through its own in-house R&D team. Most patients ailing from mild to moderate symptoms can benefit from the use of Ivejaj. The drug will be available as a prescription-based medication, with recommended doses.
The drug controller of India's has granted permissions to supply the "Ivejaj" (Ivermectin) in the domestic as well as in overseas market.
Next Story